Abiomed Celebrates 2017 American Heart Month
February 21 2017 - 11:06AM
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough
heart support technologies, is proud to support February’s American
Heart Month. Throughout the month, the company is sharing stories
of patients with heart failure and cardiogenic shock, as it works
to advance the science of heart recovery and provide patients with
innovative therapies. Abiomed is maker of Impella®, the world’s
smallest heart pump.
“Heart month is an opportunity to draw attention to advances in
technology and protocols that are saving and improving lives, while
renewing our focus on the unique challenges that exist in treating
women with cardiovascular disease, America’s top killer,” said
Michael R. Minogue, Abiomed President, Chairman and Chief Executive
Officer. “As the only developer of percutaneous heart pumps that
allow the heart to rest and recover its native function, we are
committed to helping reduce the growing impact of heart failure in
America and around the world.”
Throughout the month Abiomed is spotlighting patients
successfully treated with Impella including three young women who
will be recognized at Boston’s Go Red for Women luncheon on Friday,
February 24th. After the event, the survivors will visit the
Abiomed production teams that made their Impella devices.
- Christine Alber, 26, suffered from symptoms that were thought
to be bronchitis before collapsing and being found unconscious at
home. Physicians discovered she had a complete heart block and was
in cardiogenic shock. Cardiogenic shock occurs when the heart
suddenly cannot pump enough blood and oxygen to the body’s vital
organs like the brain and kidneys and they start to shut down. Ms.
Alber received Impella heart pump so her heart could rest and
recover. After rehabilitation to re-learn tasks like getting out of
bed and walking, she has returned to her daily and active life,
including exercising, traveling and designing handbags.
- Michelle Kellim, 38, was a healthy, active wife and mom of two
young children who went into cardiogenic shock in her sleep.
Support from Impella heart pump gave Ms. Kellim’s heart a chance to
rest and ultimately recover. Today, she continues to raise her
family, live an active lifestyle, and work with the American Heart
Association to spread awareness about heart recovery.
- Brenda Dively, a 48-year-old pre-kindergarten teacher, awoke
feeling ill. She continued to go to work but on the weekend she
deteriorated. Brenda’s husband called 9-1-1 and an ambulance team
confirmed she was having a heart attack. In intensive care, Brenda
coded and required CPR and shock to regain a pulse. The next day,
her doctor implanted the Impella CP® while he placed two stents
(while Brenda was conscious). The following week, Brenda went to
cardiac rehab and returned home two weeks later. At the time of her
event, Brenda’s Ejection Fraction was less than 20%. After a recent
echo, her EF is now at 50-55%. Brenda is also back at work with the
kids.
“These women, and the thousands of others who have been treated
with Impella, continue to inspire us each day to advance care for
high-risk heart failure patients. We are committed to treating
these patients who are our sisters, mothers, daughters and we need
to provide them with the treatments that focus on the ultimate goal
of native heart recovery,” said Minogue.
In recent months, Abiomed has received Food and Drug
Administration (FDA) approval for new indications for its Impella
line of heart pumps. In Dec. 2016, the Impella CP® device was
approved for use in elective and urgent high-risk percutaneous
coronary interventions (PCI). Impella devices received approval in
April 2016 for use in treating cardiogenic shock after heart attack
or heart surgery.
Impella is smaller than the width of a pencil and is inserted
percutaneously, delivering 2.5 to 5 liters of blood flow per minute
to the heart. It is the only FDA-approved percutaneous hemodynamic
support device determined to be safe and effective for the
treatment of elective and urgent high risk patients, and for those
in cardiogenic shock.
For more information about heart failure, treatment with Impella
and patient stories, visit ProtectedPCI.com, Abiomed on Facebook or
@AbiomedImpella on Twitter.
Founded in 1981 in Danvers, Massachusetts,
Abiomed develops and manufactures Impella, a line of the world's
smallest heart pumps that are inserted minimally invasively in a
hospital catheterization lab without the need for surgery. The
Impella heart pumps are in over 1,200 U.S. hospitals and are used
in 98% of the top U.S. heart hospitals.
ABOUT IMPELLAThe Impella 2.5®,
Impella CP® and Impella 5.0® are FDA-approved to treat heart attack
patients in cardiogenic shock, and have the unique ability to
enable native heart recovery, allowing patients to return home with
their own heart. The Impella 2.5 and Impella CP® are also approved
to treat certain advanced heart failure patients undergoing
elective percutaneous coronary interventions (PCI) such as stenting
or balloon angioplasty, to re-open blocked coronary arteries.
Abiomed's right-side heart pump, the Impella RP®, is approved to
treat certain patients experiencing right heart failure.
The Impella line of heart pumps is not right for
all patients. Speak to your cardiologist to determine whether
treatment with an Impella device is right for you. To learn
more about the Impella platform of heart pumps, including their
approved indications and important safety and risk information
associated with the use of the devices, please visit:
www.ProtectedPCI.com.
The ABIOMED logo, ABIOMED, Impella, Impella CP, and Impella RP
are registered trademarks of Abiomed, Inc. in the U.S. and in
certain foreign countries. Impella 2.5, Impella 5.0, and Recovering
hearts. Saving lives. are trademarks of Abiomed,
Inc.
ABOUT ABIOMED Based in Danvers, Massachusetts,
Abiomed, Inc. is a leading provider of medical devices that provide
circulatory support. Our products are designed to enable the
heart to rest by improving blood flow and/or performing the pumping
of the heart. For additional information, please visit:
www.abiomed.com.
FORWARD-LOOKING STATEMENTS This release
contains forward-looking statements, including statements regarding
development of Abiomed's existing and new products, the Company's
progress toward commercial growth, and future opportunities and
expected regulatory approvals. The Company's actual results may
differ materially from those anticipated in these forward-looking
statements based upon a number of factors, including uncertainties
associated with development, testing and related regulatory
approvals, including the potential for future losses, complex
manufacturing, high quality requirements, dependence on limited
sources of supply, competition, technological change, government
regulation, litigation matters, future capital needs and
uncertainty of additional financing, and other risks and challenges
detailed in the Company's filings with the Securities and Exchange
Commission, including the most recently filed Annual Report on Form
10-K and Quarterly Report on Form 10-Q. Readers are cautioned not
to place undue reliance on any forward-looking statements, which
speak only as of the date of this release. The Company undertakes
no obligation to publicly release the results of any revisions to
these forward-looking statements that may be made to reflect events
or circumstances that occur after the date of this release or to
reflect the occurrence of unanticipated events.
For further information please contact:
Adrienne Smith
Senior Director, Public Relations and Corporate Communications
978-646-1553
adsmith@abiomed.com
Ingrid Goldberg
Director, Investor Relations
978-646-1590
igoldberg@abiomed.com
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Apr 2024 to May 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From May 2023 to May 2024